Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phenolic compound metabolism by gut bacteria refers to the collective set of enzymatic processes carried out primarily in the colon by diverse members of the human intestinal microbiota. These microbes transform dietary polyphenols—plant-derived secondary metabolites with antioxidant and anti-inflammatory properties—into smaller molecules that are more readily absorbed into circulation. The transformation involves various reactions such as hydrolysis, ring fission, reduction, demethylation, decarboxylation, dihydroxylation, and isomerization. Key bacterial genera involved include Bacteroides, Eubacterium, Roseburia, Butyrivibrio (Lachnospiraceae), Ruminococcus, Faecalibacterium prausnitzii for xylan degradation and release/reduction of ferulic acid from plant cell walls; other species like Lactobacillus plantarum IFPL935 or Eggerthella lenta participate in flavan–3–ol conversion into valerolactones[1][2]. This metabolic activity has significant implications for human health because it determines both the availability and biological effects of polyphenols after ingestion. The resulting microbial metabolites have been associated with beneficial outcomes including improved cardiovascular health through inhibition of platelet activation or modulation of insulin signaling; neuroprotection via blood-brain barrier-permeable compounds; anti-cancer activities; modulation of inflammation; prebiotic stimulation favoring beneficial bacterial families like Bifidobacteriaceae/Lactobacillaceae while suppressing pathogens[1][2][3]. However, "Phenolic compound metabolism by gut bacteria" is not itself a single molecular entity or canonical drug target but rather describes an ecological/metabolic function distributed across many taxa within the microbiome using diverse enzymatic machinery. As such it does not fit standard definitions for therapeutic targets like receptors or enzymes. Therefore: • This entry should be flagged as incorrect if used where a discrete molecular target is required. • It represents an important functional axis at the interface between diet/microbiome/host physiology but cannot be mapped onto one gene/protein/receptor/enzyme. • Research continues into identifying key strains/enzymes responsible for specific transformations within this broad category.[4]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phenolic compound metabolism by gut bacteria.